TurnerTrends Stock Rating Report for CELG
Data valid for week beginning August 25, 2008
|
CELG [News]
|
Celgene Corporation
|
Company Profile
"Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States. Its primary commercial stage products include REVLIMID (lenalidomide) for the treatment in combination with dexamethasone for multiple myeloma patients who have received at least one prior therapy, as well as for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated (MDS) with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities- and THALOMID (thalidomide) for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum, an inflammatory complication of leprosy. The company also sells ALKERAN, through a supply and distribution agreement with GlaxoSmithKline, for the palliative treatment of multiple myeloma and of carcinoma of the ovary- and FOCALIN for the treatment of oncology-related disorders. Celgene's products in pipeline primarily include CC-4047, a Phase III clinical trial product for the treatment of sickle cell anemia- CC-10004, a Phase II product for Psoriasis Psoriatic arthritis inflammatory diseases- and CC-11006, a Phase I-II trial product in MDS, for Hematological malignances. Celgene Corporation has a strategic collaboration with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011. The company was founded in 1980 and is headquartered in Summit, New Jersey."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Wed, 20 Aug 2008 21:45:59 Etc/GMT | Final Glance: Biotechnology companies (AP) | | Wed, 20 Aug 2008 17:07:48 Etc/GMT | Midday Glance: Biotechnology companies (AP) | | Wed, 20 Aug 2008 14:51:11 Etc/GMT | Early Glance: Biotechnology companies (AP) | | Wed, 20 Aug 2008 04:24:00 Etc/GMT | Peter Brimelow: Is medical technology stock letter about to Matterhorn again? (at MarketWatch) | | Tue, 19 Aug 2008 21:51:37 Etc/GMT | Final Glance: Biotechnology companies (AP) | | Tue, 19 Aug 2008 20:12:12 Etc/GMT | Health Winners & Losers: Medtronic (at TheStreet.com) | | Tue, 19 Aug 2008 18:10:21 Etc/GMT | Midday Glance: Biotechnology companies (AP) | | Tue, 19 Aug 2008 14:36:56 Etc/GMT | Early Glance: Biotechnology companies (AP) | | Mon, 18 Aug 2008 21:55:40 Etc/GMT | Final Glance: Biotechnology companies (AP) | | Mon, 18 Aug 2008 20:05:06 Etc/GMT | Funds for a Sick Economy? (at Motley Fool) | | Mon, 18 Aug 2008 18:00:59 Etc/GMT | [$$] Fitz Bits: Bottom-Picking Valero (at RealMoney by TheStreet.com) | | Mon, 18 Aug 2008 16:58:02 Etc/GMT | Midday Glance: Biotechnology companies (AP) | | Mon, 18 Aug 2008 14:53:59 Etc/GMT | Early Glance: Biotechnology companies (AP) | | Fri, 15 Aug 2008 21:46:36 Etc/GMT | Final Glance: Biotechnology companies (AP) | | Fri, 15 Aug 2008 18:25:01 Etc/GMT | Early Signs of Winning Stocks (at Motley Fool) | | Fri, 15 Aug 2008 17:47:01 Etc/GMT | Midday Glance: Biotechnology companies (AP) | | Fri, 15 Aug 2008 15:14:55 Etc/GMT | Early Glance: Biotechnology companies (AP) | | Thu, 14 Aug 2008 21:47:01 Etc/GMT | Final Glance: Biotechnology companies (AP) | | Thu, 14 Aug 2008 20:02:58 Etc/GMT | 'Fast Money' Recap: Find the Best Banks (at TheStreet.com) | | Thu, 14 Aug 2008 17:44:17 Etc/GMT | Midday Glance: Biotechnology companies (AP) | News provided by Yahoo! Finance |
|
